In addition, HER2-positive GC subtypes exhibit divergent signalling pathway activation (e.g. PI3K/AKT vs. MAPK), genomic instability profiles, and immune microenvironment compositions [13, 14]. The gene discussed is ERBB2; the disease is gastric cancer.